MARKET

NMTR

NMTR

9 Meters Biopharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2249
-0.0359
-13.77%
After Hours: 0.2200 -0.0049 -2.18% 19:59 07/01 EDT
OPEN
0.2664
PREV CLOSE
0.2608
HIGH
0.2799
LOW
0.2249
VOLUME
10.78M
TURNOVER
0
52 WEEK HIGH
1.460
52 WEEK LOW
0.2210
MARKET CAP
58.27M
P/E (TTM)
-1.3427
1D
5D
1M
3M
1Y
5Y
--Maxim Downgrades 9 Meters Biopharma to Hold From Buy
MT Newswires · 4d ago
9 Meters gets $70M debt facility for phase 3 development of short bowel syndrome drug
9 Meters Biopharma (NASDAQ:NMTR) on Thursday <a href="https://...
Seekingalpha · 5d ago
BRIEF-9 Meters Biopharma Entered Into Securities Purchase Agreement For Purchase Of Senior Secured Convertible Notes With Institutional Investor
BRIEF-9 Meters Biopharma Entered Into Securities Purchase Agreement For Purchase Of Senior Secured Convertible Notes With Institutional Investor
Reuters · 5d ago
9 Meters stock falls despite drug showing promise in short bowel syndrome trial
9 Meters Biopharma (NASDAQ:NMTR) <a href="https://seekingalpha...
Seekingalpha · 5d ago
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel SyndromeRALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people wit...
ACCESSWIRE · 5d ago
9 Meters Biopharma Announces Preliminary Results From Phase 2 Study Of Vurolenatide In Short Bowel Syndrome
Phase 2 VIBRANT study identifies a dose and dosing interval with >25% improvement in the primary endpoint of 24-hour mean total stool output reduction over 6 weeks Vurolenatide was generally well tolerated with no
Benzinga · 5d ago
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
(NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced positive preliminary topline results from the VIBRANT study (VurolenatIde for short Bowel syndrome Regardless of pA...
ACCESSWIRE · 5d ago
9 Meters Biopharma Secures Debt Facility for Up to $70 Million
MT Newswires · 5d ago
More
No Data
Learn about the latest financial forecast of NMTR. Analyze the recent business situations of 9 Meters Biopharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
50.00%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NMTR stock price target is 3.250 with a high estimate of 4.000 and a low estimate of 2.000.
High4.000
Average3.250
Low2.000
Current 0.2132
EPS
Actual
Estimate
-0.04-0.03-0.02-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 106
Institutional Holdings: 75.72M
% Owned: 29.22%
Shares Outstanding: 259.11M
TypeInstitutionsShares
Increased
19
758.73K
New
13
2.37M
Decreased
32
1.49M
Sold Out
16
5.00M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.48%
Pharmaceuticals & Medical Research
+0.08%
Key Executives
Non-Executive Chairman/Independent Director
Mark Sirgo
President/Chief Executive Officer/Director
John Temperato
Chief Financial Officer
Bethany Sensenig
Other
Sarah Liu
Independent Director
Michael Constantino
Independent Director
Lorin Johnson
Independent Director
Michael Rice
Independent Director
Samantha Ventimiglia
No Data
No Data
About NMTR
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.

Webull offers kinds of 9 Meters Biopharma Inc stock information, including NASDAQ:NMTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NMTR stock methods without spending real money on the virtual paper trading platform.